Biogen Completes Acquisition of Ray Thera

{
  "signal_id": "312b0f03-487c-ca2b-a107-197d4d561131",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-08-07T13:30:23+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "url": "https://www.pharmabiz.net/biogen-completa-compra-de-ray-thera/",
    "title": "Biogen Completes Acquisition of Ray Thera - pharmabiz.net",
    "excerpt": "US-based Biogen finalized the announced acquisition of its compatriot Ray Thera, a private biotechnology company dedicated to the discovery and development of small molecule therapies in the field of immunology. The deal is valued at up to US$1,000M, including an upfront payment and other complementary payments subject to the achievement of future clinical and regulatory milestones. In less than two months, the multinational led by Christopher Viehbacher managed to conclude the acquisition of Ray Thera, in an operation designed with the aim of strengthening its growing portfolio of immunological products. See Press Release RayThera's pipeline includes multiple anti-inflammatory assets with the potential to treat immune-mediated diseases across various indications. The lead candidate is expected to enter Phase I development in early Q3 2026. The operation, which had been announced on June 17, is valued at up to US$1,000 million, which is divided into an initial payment and other complementary payments subject to the achievement of future clinical and regulatory milestones. See Biogen acquires RayThera, immuno In Argentina, last year Andrea da Pieve's tenure leading the local market ended. She was replaced by Agustín Lamas, the former general manager of AZ during the COVID-19 pandemic and who came from the technology company Globant. See Agustín Lamas to Biogen Note: at...",
    "summary": "Biogen has completed its acquisition of Ray Thera, a private biotechnology company, in a deal valued at up to $1 billion.",
    "location": "United States",
    "planning": false,
    "image_url": "https://www.pharmabiz.net/wp-content/uploads/2026/07/Biogen-Headquarter-26-e1785253742602.jpg",
    "confidence": 0.95,
    "published_at": "2026-08-07T13:30:23Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "US-based Biogen finalized the announced acquisition of its compatriot Ray Thera, a private biotechnology company dedicated to the discovery and development of small molecule therapies in the field of immunology.",
    "amount_normalized": 1000000000,
    "related_company_name": "Ray Thera",
    "related_company_domain": "raythera.com"
  }
}

curl https://signals.autobound.ai/v1/signals/312b0f03-487c-ca2b-a107-197d4d561131 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","limit":20}'